ALLMedicine™ Hairy Cell Leukemia Center
Research & Reviews 373 results
https://clinicaltrials.gov/ct2/show/NCT01087333
Jun 24th, 2022 - Background Hairy cell leukemia (HCL) is highly responsive to but not curable by standard chemotherapy, and also responds well to investigational agents called recombinant immunotoxins which have been developed by the Laboratory of Molecular Biolog...
https://clinicaltrials.gov/ct2/show/NCT01059786
Jun 24th, 2022 - Background: Hairy cell leukemia (HCL) is highly responsive to purine analogs cladribine and pentostatin, without evidence of cure. Neither is standard after 2 courses, due to cumulative marrow and T-cell toxicity and declining remission rates and ...
https://clinicaltrials.gov/ct2/show/NCT00923013
Jun 24th, 2022 - Background: Hairy cell leukemia (HCL) is highly responsive to but not curable by cladribine (CdA). HCL responds to rituximab, which is not yet standard therapy for HCL. Patients with the CD25-negative variant (HCLv) respond poorly to initial cladr...
https://clinicaltrials.gov/ct2/show/NCT04815356
Jun 24th, 2022 - Background Hairy cell leukemia (HCL) is an indolent CD22+ B-cell leukemia comprising 2% of all leukemias. Most cases of HCL respond well to purine analog chemotherapy and harbor BRAF V600E mutation that can be considered for targeted treatment at ...
https://clinicaltrials.gov/ct2/show/NCT03805932
Jun 24th, 2022 - Background: Hairy cell leukemia (HCL) is an indolent CD22+ B-cell leukemia comprising 2% of all leukemias, or approximately 1200 of the 62,130 new cases of leukemia/year in the US. HCL variant (HCLv), also CD22+, is 10-20% as common as HCL, but mo...
Guidelines 1 results
https://doi.org/10.6004/jnccn.2017.0165
Journal of the National Comprehensive Cancer Network : JN... Wierda WG, Byrd JC et. al.
Nov 10th, 2017 - Hairy cell leukemia (HCL) is a rare type of indolent B-cell leukemia, characterized by symptoms of fatigue and weakness, organomegaly, pancytopenia, and recurrent opportunistic infections. Classic HCL should be considered a distinct clinical entit...
Drugs 9 results see all →
Clinicaltrials.gov 38 results
https://clinicaltrials.gov/ct2/show/NCT04815356
Jun 24th, 2022 - Background Hairy cell leukemia (HCL) is an indolent CD22+ B-cell leukemia comprising 2% of all leukemias. Most cases of HCL respond well to purine analog chemotherapy and harbor BRAF V600E mutation that can be considered for targeted treatment at ...
https://clinicaltrials.gov/ct2/show/NCT04322383
Jun 24th, 2022 - Background: Hairy cell leukemia (HCL) is an indolent B-cell leukemia comprising 2% of all leukemias, or approximately 1900 new cases per year in the US. BRAF V600E mutation is very common in classic HCL. HCL variant (HCLv) is wild type for BRAF an...
https://clinicaltrials.gov/ct2/show/NCT04362865
Jun 24th, 2022 - Background: Patients infected with COVID-19 have an unpredictable risk to worsen and die, making it difficult to decide who can quarantine at home and who should be monitored for respiratory failure as an inpatient. This risk may be related in par...
https://clinicaltrials.gov/ct2/show/NCT01087333
Jun 24th, 2022 - Background Hairy cell leukemia (HCL) is highly responsive to but not curable by standard chemotherapy, and also responds well to investigational agents called recombinant immunotoxins which have been developed by the Laboratory of Molecular Biolog...
https://clinicaltrials.gov/ct2/show/NCT01059786
Jun 24th, 2022 - Background: Hairy cell leukemia (HCL) is highly responsive to purine analogs cladribine and pentostatin, without evidence of cure. Neither is standard after 2 courses, due to cumulative marrow and T-cell toxicity and declining remission rates and ...
News 74 results
https://www.onclive.com/view/targeted-combo-notches-rare-success-in-glioblastoma
Mar 30th, 2022 - For more than 20 years, investigators have tried numerous targeted therapy strategies against glioblastoma (GBM) that have fallen frustratingly short in establishing clinical benefit.1 That changed in November 2021 when an international team of in...
https://www.onclive.com/view/dr-park-on-vemurafenib-in-hairy-cell-leukemia
Oct 6th, 2021 - Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Memorial Hospital, discusses vemurafenib in hairy cell leukemia. Park says the first breakthrough in hairy cell leukemia came in the 1980s when physicians learned that ...
https://www.onclive.com/view/selumetinib-response-not-driven-by-mapk-expression-in-pediatric-and-aya-refractory-solid-tumors
Jun 10th, 2021 - Selumetinib did not elicit clinical activity in pediatric and young adult patients with refractory cancers who had actionable mutations in the RAS/RAF/MAPK1/2-ERK pathway, according to cohort findings from the phase 2, single-arm National Cancer I...
https://www.onclive.com/view/dr-ailawadhi-on-the-efficacy-of-lisaftoclax-in-hematologic-malignancies
Jun 7th, 2021 - Sikander Ailawadhi, MD, professor of medicine, Division of Hematology/Oncology, Departments of Medicine and Cancer Biology, Mayo Clinic, discusses the activity of lisaftoclax in patients with hematologic malignancies. Lisaftoclax was evaluated ...
https://www.onclive.com/view/lisaftoclax-shows-early-safety-efficacy-in-relapsed-refractory-cll-sll-and-other-hematologic-cancers
Jun 7th, 2021 - The novel BCL-2 inhibitor lisaftoclax (APG-2575) elicited encouraging responses with acceptable tolerability in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) and other hematologic cancers, according to data ...
